Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D-CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results.© 2014 American Society for Clinical Pharmacology and Therapeutics.
CITATION STYLE
Clancy, J. P., Johnson, S. G., Yee, S. W., Mcdonagh, E. M., Caudle, K. E., Klein, T. E., … Giacomini, K. M. (2014). Clinical pharmacogenetics implementation consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clinical Pharmacology and Therapeutics, 95(6), 592–597. https://doi.org/10.1038/clpt.2014.54
Mendeley helps you to discover research relevant for your work.